Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Last trade$14.82
Day change-$0.31 (-2.05%)
Day range$14.59 – $15.45
Volume1,099,079
Market cap$1.62B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.62B
Price / earnings
109.92×
Price / book
1.06×
Price / sales
0.83×
EV / sales
1.03×
EV / EBITDA
84.49×
Profitability
Earnings per share
$0.14
Return on assets
0.47%
Return on equity
0.97%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.56×
Current ratio
3.46×
Quick ratio
2.13×
Cash ratio
0.72×
Cash flow
Price / cash flow
8.74×
Price / free cash flow
9.2×
Free cash flow
$176.4M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SRPT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$381.35M
$401.25M
$730.8M
$442.93M
$399.36M
$611.09M
$744.86M
$658.41M
Cost of revenue
$188.51M
$149.39M
$108.77M
$398.71M
$150.78M
$152.56M
$137.56M
$132.3M
Gross profit
$192.84M
$251.87M
$622.04M
$44.23M
$248.58M
$458.53M
$607.29M
$526.11M
Selling, general and administrative
$118.61M
$107.6M
$108.95M
$128.3M
$91.89M
$137.9M
$133.63M
$163.87M
Research and development
$82.55M
$91.26M
$153.96M
$325.34M
$218.89M
$204.39M
$773.45M
$199.95M
Total operating expenses
$201.88M
$238.58M
$263.6M
$455.81M
$351.97M
$342.96M
$907.68M
$364.43M
Operating income
-$9.04M
$13.29M
$358.43M
-$411.58M
-$103.39M
$115.58M
-$300.39M
$161.68M
Interest expense
-$21.62M
$0
$0
$0
-$9.46M
$0
$0
$0
Income before taxes
-$25.77M
-$1.75M
$343.17M
-$278.3M
-$64.67M
$153.64M
-$383.52M
$171.74M
Income taxes
$2.7M
$3.14M
$12.22M
$4.55M
-$14.1M
-$43.25M
$63.99M
$12.69M
Net income
-$28.46M
-$4.89M
$330.96M
-$282.85M
-$50.57M
$196.89M
-$447.51M
$159.05M
Net income attributable to common shareholders
-$28.46M
-$4.89M
$330.96M
-$282.85M
-$50.57M
$196.89M
-$447.51M
$159.05M
EBITDA
-$3.14M
$62.7M
$369.03M
-$404.83M
-$44.43M
$126.42M
-$290.41M
$172.14M
Basic earnings per share
-$0.27
-$0.05
$3.15
-$2.70
-$0.50
$2.01
-$4.60
$1.65
Diluted earnings per share
-$0.27
-$0.05
$2.88
-$2.94
-$0.50
$1.89
-$4.60
$1.20
Recent news
Company coverage with links to the original publishers.
Sarepta Therapeutics reported Q3 2026 adjusted EPS of 13 cents, missing estimates of 37 cents, though revenues of $381.4M beat expectations. Elevidys gene therapy sales underperformed at $83.5M, while PMO therapies exceeded estimates at $240.3M. The company raised 2026 product revenue guidance to $1.25-$1.3B, supported by strong PMO franchise performance. Stock declined 3.4% after-hours on mixed results.
Sarepta Therapeutics (SRPT) reported quarterly earnings of $0.13 per share, missing consensus estimates of $0.37 per share, representing a -64.87% earnings surprise. While revenues of $381.35 million exceeded expectations by 9.43%, the company received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revisions. The stock has underperformed the S&P 500 by 24.1% year-to-date.
Sarepta Therapeutics reported Q3 2026 revenue of $381.35 million, beating consensus estimates by 9.43% but declining 4.5% year-over-year. However, the company delivered a significant EPS miss, reporting $0.13 versus the consensus estimate of $0.37, representing a -64.87% surprise. Key product revenues showed mixed results, with PMO Products growing 0.7% YoY and Collaboration revenue surging 96.5%, while ELEVIDYS revenue declined 36.3% YoY. The stock carries a Zacks Rank #5 (Strong Sell) rating.
Sarepta Therapeutics is expected to report Q3 2026 earnings of $0.37 per share (up 384.6% YoY) but with revenues declining 12.7% to $348.48 million. However, consensus EPS estimates have been revised 77.14% lower in the last 30 days, and the stock carries a Zacks Rank #5 with a negative Earnings ESP of -28.96%, making it an unlikely earnings-beat candidate.
Zacks Research Daily features analysis of 16 major stocks on October 6, 2026. SpaceX benefits from reusable launch technology and Starlink expansion but faces capital requirements. Dell outperforms due to AI infrastructure demand and broad portfolio strength. KLA gains from AI-driven semiconductor demand and process-control intensity. Additional coverage includes analysis of Lockheed Martin's expanded backlog, Deere's pricing actions offsetting commodity headwinds, and concerns about Sarepta's concentrated DMD focus.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.